<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03144167</url>
  </required_header>
  <id_info>
    <org_study_id>PI2016_843_0027</org_study_id>
    <nct_id>NCT03144167</nct_id>
  </id_info>
  <brief_title>Study of Prognostic Biomarkers of Survival at 6 Months for Patients Treated With Bevacizumab Glioblastomas in First Relapse After Failure of Radiochemotherapy</brief_title>
  <acronym>SPECTROBEVA</acronym>
  <official_title>Study of Prognostic Biomarkers of Survival at 6 Months for Patients Treated With Bevacizumab Glioblastomas in First Relapse After Failure of Radiochemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      No predictive factors are known for the response to the bevacizumab anti-angiogenic molecule&#xD;
      (Avastin) given in the event of relapse of glioblastoma (GBM) following radiochemotherapy.&#xD;
      Classical MRI with gadolinium injection and perfusion is not sufficient to predict survival&#xD;
      and response or duration. We propose to evaluate the prognostic interest for 6-month survival&#xD;
      of spectroscopic biomarkers of proliferation, glial reaction, infiltration and glutaminergic&#xD;
      metabolism or glycolytic metabolism recorded at 7 and 28 days of application of the&#xD;
      treatment.&#xD;
&#xD;
      These biomarkers are based on the increase of an index combining choline / Creatine (Cho /&#xD;
      Cr), Glx / Cr (Glutamine and glutamate / Creatine), NAA / Cr (N acetyl aspartate / Creatine)&#xD;
      and lactate / Cr ratios. The long-term objective is to predict the survival of these relapsed&#xD;
      GBM patients at an early stage and to identify responder patients who would benefit from this&#xD;
      expensive molecule and avoid using it in non-responding patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">August 20, 2017</start_date>
  <completion_date type="Anticipated">January 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">January 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analyze 6-month survival defined as the time between inclusion in the protocol and death</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Radiotherapy</condition>
  <condition>Chemotherapy</condition>
  <arm_group>
    <arm_group_label>Patients, aged 18-88, with glioblastoma</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Analysis of spectroscopic biomarkers of proliferation for six-month survival</intervention_name>
    <description>Analysis of spectroscopic biomarkers of proliferation, glial reaction, infiltration and glutaminergic metabolism or glycolytic metabolism for six-month survival</description>
    <arm_group_label>Patients, aged 18-88, with glioblastoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients, between 18 and 88 years, with glioblastoma (histologically proven) in first&#xD;
             relapse after conventional treatment by surgery and temozolomide and radiotherapy&#xD;
&#xD;
          -  Biological Criteria&#xD;
&#xD;
               -  Polymorphonuclear neutrophils&gt; 1500 / mm3&#xD;
&#xD;
               -  Plates&gt; 100,000 / mm3&#xD;
&#xD;
               -  SGOT-SGPT &lt;5 at the upper limit of normal (ULN)&#xD;
&#xD;
               -  Bilirubin &lt;1.5 x ULN&#xD;
&#xD;
               -  Creatinine &lt;1.5 LSN and creatinine clearance&#xD;
&#xD;
               -  Proteinuria &lt;1 g / 24 hours&#xD;
&#xD;
               -  Patient with health insurance&#xD;
&#xD;
               -  Consent signed by the patient if he is lucid, or failing that by the person of&#xD;
                  trust&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who can not benefit from bevacizumab for the following reasons:&#xD;
&#xD;
               -  Symptomatic cerebral or tumor hemorrhage&#xD;
&#xD;
               -  Karnofsky Index less than 50% or&#xD;
&#xD;
          -  Patients already treated with an antiangiogenic molecule or Gliadel (diagnosis and&#xD;
             recurrence).&#xD;
&#xD;
          -  Coagulation disorders in case of injectable treatment (especially for avastin),&#xD;
&#xD;
          -  Contraindications known to the MRI: Pace Makers, foreign bodies intraocular,&#xD;
             electrodes ...&#xD;
&#xD;
          -  Uncontrolled severe concomitant pathology, including another evolving cancer (with the&#xD;
             exception of operative cutaneous tumors, in situ cancer of the cervix or breast&#xD;
             treated).&#xD;
&#xD;
          -  Uncontrolled Infection&#xD;
&#xD;
          -  Uncontrolled hypertension (PAS&gt; 160 mm Hg) despite optimized treatment&#xD;
&#xD;
          -  Coronary artery disease or unstable arterial disease. Evolutionary aneurysm.&#xD;
&#xD;
          -  Myocardial infarction dating from less than 6 months.&#xD;
&#xD;
          -  Peripheral arterial or cerebrovascular accident occurring less than 6 months.&#xD;
&#xD;
          -  Heart Failure&gt; grade II NYHA&#xD;
&#xD;
          -  Hemorrhagic Disease (Hemophilia, Willebrandt ...)&#xD;
&#xD;
          -  Nephrotic syndrome with proteinuria&gt; 2 g / 24 h&#xD;
&#xD;
          -  History of haemoptysis dating less than 1 month.&#xD;
&#xD;
          -  Pulmonary embolism dating less than 1 month.&#xD;
&#xD;
          -  Surgical intervention (other than craniotomy or stereotactic biopsy) dating less than&#xD;
             one month or essential and predictable surgery.&#xD;
&#xD;
          -  History of digestive fistula or intestinal perforation with resolution less than 6&#xD;
             months.&#xD;
&#xD;
          -  Hypersensitivity to bevacizumab or to any of the excipients mentioned in Composition.&#xD;
&#xD;
          -  Hypersensitivity to Chinese hamster ovary (CHO) cells or to other human or humanized&#xD;
             recombinant antibodies.&#xD;
&#xD;
          -  Severe Myelosuppression&#xD;
&#xD;
          -  Pregnant or nursing. Contraception should be prescribed if necessary during treatment.&#xD;
&#xD;
          -  Persons deprived of liberty or placed under safeguard of justice (guardianship or&#xD;
             curatorship),&#xD;
&#xD;
          -  Subject involved in another search including an exclusion period still in progress at&#xD;
             pre-inclusion&#xD;
&#xD;
          -  Patient refusing to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Marc CONSTANS, PhD</last_name>
    <phone>+33322087511</phone>
    <email>constans.jean-marc@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens Picardie</name>
      <address>
        <city>Amiens</city>
        <state>Picardie</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jean-Marc CONSTANS, PhD</last_name>
      <phone>+33322087511</phone>
      <email>constans.jean-marc@chu-amiens.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>April 27, 2017</study_first_submitted>
  <study_first_submitted_qc>May 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2017</study_first_posted>
  <last_update_submitted>July 19, 2017</last_update_submitted>
  <last_update_submitted_qc>July 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

